Three founders. One category.
Atumnus Life Sciences is held by three founding-tier principals. Two decades of natural-formulation curation, full-stack IP and AI architecture, and the commercial direction of a category authority — held together by a working agreement that each layer of the category requires its own depth and its own person.
Ian Clark
Two decades of global natural-formulation sourcing, brought into the founding team.
Ian is the Founder and CEO of Activation Products and a founding-tier equity holder in the Opticeutical category. Following a 2004 health crisis that he addressed through natural means rather than conventional intervention, Ian spent the next two decades traveling the world to identify potent natural formulations, heritage compounds, and sourcing relationships that conventional supply chains overlook.
He served as Curator of Longevity Protocols at Healing Modalities Research from 2007 to 2014 before founding Activation Products with his son Anthony. At Atumnus, his role as Founding Curator anchors the category's standards for sourcing integrity, natural-formulation discovery, and the institutional knowledge of what works that informs the Opticeutical Standard's sourcing pillar.
Ian has appeared in long-form on Jim Kwik's Kwik Brain podcast, Darin Olien's SuperLife, Josh Trent's Wellness Force, Melanie Avalon's Biohacking Podcast, Ben Greenfield Life, Brian Gryn's Get Lean Eat Clean, Dr. Stephanie Canestraro's What Happens in Vagus, and the Chris Voss Show, among many others. He appears in the Biohack Yourself feature documentary series alongside Robert F. Kennedy Jr., Dave Asprey, Daniel Amen, Mindy Pelz, and Nathan Bryan. The full conversation archive is published on this site.
- Founder and CEO, Activation Products
- Curator of Longevity Protocols, Healing Modalities Research (2007–2014)
- Biohack Yourself Documentary Series (Chapter 2 — Healthspanning Our Longevity)
- Kwik Brain Podcast (Episode 242)
Daniel Nowak
Full-stack AI infrastructure, IP architecture, and the technical foundation behind the Opticeutical category.
Daniel is the Founder and Chief Technology Officer of Atumnus Life Sciences. He is the architect of the intellectual property portfolio that underlies the Opticeutical category — the compound architectures, delivery platforms, and Opti-Salt™ therapeutic salt carrier system — and of the HI-Centric-AI infrastructure that supports the institutional research and IP work.
His background combines two decades in dental laboratory operations and full-arch implant reconstruction with deep technical expertise in software architecture, distributed AI systems, and life-sciences product development. He has led the build of the Opticeutical category from initial research synthesis through IP filing, formulation discipline, and public category launch.
Daniel's technical work spans the full stack — from the bioregulator IP architecture and the Opti-Salt™ carrier system, through the HI-Centric-AI institutional infrastructure, to the consumer-facing surfaces that the category authority publishes. The architecture is designed so that every layer of the category can be operated by a small institutional team with the discipline of a much larger one.
- Architect, Atumnus Life Sciences IP portfolio
- Lead developer, HI-Centric-AI institutional infrastructure
- Two decades of life-sciences product and laboratory operations
Daniel William Dorsey
Strategic direction, commercial architecture, and the institutional voice of the category steward.
Daniel is the Co-Founder and Chief Executive Officer of Atumnus Life Sciences. He holds the strategic and commercial direction of the company, including the institutional posture of the category steward, the partnership architecture, and the public voice through which the Opticeutical category is articulated.
Bio in development. Additional detail to follow as the founding-team materials are finalized for publication.
- Co-Founder, Atumnus Life Sciences
The board takes shape.
Atumnus Life Sciences is assembling a scientific and strategic advisory group spanning peptide chemistry and synthesis, regulatory strategy, clinical channel development, and bioelectric regeneration research. Advisor appointments will be published as agreements are finalized.
Qualified scientific advisors and clinical channel partners interested in the founding advisory group may request the advisor brief through the contact channel.
Read the work the founding team has put on the public record.
Two decades of conversations →
Ian Clark in long-form on Jim Kwik, Darin Olien, Ben Greenfield, Josh Trent, the Biohack Yourself documentary, and many more.
Category developments →
Twenty articles spanning the heritage of the category through the Activation Products and Atumnus Life Sciences collaboration.
The Opticeutical Standard →
Six pillars defining what qualifies a product to bear the Opticeutical name.